Factors associated with outcome in heart failure with preserved ejection fraction

Circulation: Heart Failure

Volumn 4, Issue 1, 2011, Pages 27-35

  Komajda, Michel ^a   Carson, Peter E ^b   Hetzel, Scott ^c   McKelvie, Robert ^d   McMurray, John ^e   Ptaszynska, Agata ^f   Zile, Michael R ^g   DeMets, David ^c   Massie, Barry M ^h  

^a SORBONNE UNIVERSITÉ   (France)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f BRISTOL MYERS SQUIBB   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heart failure; Outcome; Preserved ejection fraction; Prognosis evaluation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; IRBESARTAN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TETRAZOLE DERIVATIVE;

AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HEART STROKE VOLUME; KAPLAN MEIER METHOD; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; FEMALE; HEART FAILURE; HEART RATE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; NEUTROPHILS; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME;

EID: 79952270444     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.932996     Document Type: Article

References (40)

1. Lenzen MJ, Scholte OP, Reimer WJ, Boersma E, Vantrimpont PJMJ, Follath F, Swedberg K, Cleland J, Komajda M. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeartFailure Survey. Eur Heart J. 2004;25: 1214-1220. (Pubitemid 38891571)
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. (Pubitemid 44079340)
3. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260 -269. (Pubitemid 44088349)
4. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-327. (Pubitemid 38167688)
5. Yancy CW, Lopatin M, Stevenson LW, de Marco T, Fonarrow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76-84. (Pubitemid 43005168)
6. Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med. 2000;109:605-613.
7. Fonarrow GC, Stough WG, Abraham WT, Albert N, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB, for the OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with Preserved Systolic Function Hospitalized for Heart Failure. J Am Coll Cardiol. 2007;50:768-777. (Pubitemid 47243795)
8. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail. 2009;11:855-862.
9. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G, for the I-PRESERVE Investigators. The Irbesartan in heart failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail. 2005;11:576-585. (Pubitemid 41463727)
10. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, for the I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
11. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106-1107. (Pubitemid 23126823)
12. de Groot JAH, Janssen KJM, Zwinderman AH, Moons KGM, Reitsma JB. Multiple imputation to correct for partial verification bias revisited. Stat Med. 2008;27:5880-5889.
13. Harrell FE Jr. Regression Modelling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Verlag New York, Inc; 2001.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. (Pubitemid 29135798)
15. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3:143-152. (Pubitemid 14052973)
16. Hogg K, McMurray J. Neurohormonal pathways in heart failure with preserved systolic function. Prog Cardiovasc Dis. 2005;47:357-366. (Pubitemid 41188342)
17. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AHB, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Wold Knudsen CW, Perez A, Kamin R, Kazanegra R, Hermann HC, McCullough PA, for the Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. J Am Coll Cardiol. 2003;41:2010-2017. (Pubitemid 36677124)
18. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, Goldstein S. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol. 1989;14:564-570. (Pubitemid 19229327)
19. McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Barry MM, for the I-PRESERVE Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010;16:128-134.
20. Kearney MT, Nolan J, Lee AJ, Brooksby PW, Prescott R, Shah AM, Zaman AG, Eckberg DL, Lindsay HS, Batin PD, Andrews R, Fox KA. A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. Eur J Heart. 2003;5:489-497. (Pubitemid 37021643)
21. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med. 2004;116:300-304. (Pubitemid 38230288)
22. Eichhorn EJ. Prognosis determination in heart failure. Am J Med. 2001; 110:14S-36S. (Pubitemid 33727563)
23. Rich MW, McSherry F, Williford W, Yusuf F. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38:806-813. (Pubitemid 32835757)
24. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJC, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB, on behalf of the CHARM Investigators. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65-75. (Pubitemid 41785934)
25. Domanski M, Krause-Steinfrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR, BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914-922. (Pubitemid 37059754)
26. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J. 2004;148:883-888.
27. Disegni E, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Zion M, Boyko V, Behar S. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. J Clin Epidemiol. 1995;48: 1197-1205.
28. Lechat PH, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen- Grandjean M, Pochmalicki G, Dargie H, on behalf of the CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103: 1428-1433. (Pubitemid 32220636)
29. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1:H64-H69. (Pubitemid 29304286)
30. Fox K, Ford I, Steg G, Tendera M, Robertson M, Ferrari R, on behalf of the BEAUTIFUL Investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817-821.
31. Böhm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators: heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-894.
32. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu AW. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-1233. (Pubitemid 37188347)
33. Macchia A, Monte S, Romero M, d'Ettore A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalized for chronic heart failure. Eur J Heart Fail. 2007;9:942-948. (Pubitemid 47332320)
34. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-139.
35. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) Investigators. Circulation. 2006;113:671-678.
36. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-2667. (Pubitemid 27255495)
37. Anand IS, Yen J, Folre AVG, Hester A, Glazer R, Latinin R, Maggioni A, Cohn JN. Prognostic role of neutrophil and lymphocyte counts in heart failure: results from Val-HEFT. J Am Coll Cardiol. 2004;43:229A.
38. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death and heart failure after myocardial infarction. Circulation. 2009;2:656-662.
39. Tracchi I, Ghigliotti G, Mura M. Garibaldi S, Spallarossa P, Barisione C, Boasi V, Brunelli M, Corsiglia L, Barsotti A, Brunelli C. Increased neutrophil lifespan in patients with congestive heart failure. Eur J Heart Fail. 2009;11:378-385.
40. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The SEATTLE heart failure model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. (Pubitemid 43739439)